Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of nivolumab plus gemcitabine in patients with recurrent or metastatic nasopharyngeal carcinoma (HN17-11)
KCT0003189Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, gemcitabine in nasopharyngeal carcinoma (NPC), sponsored by Ono Pharmaceutical. Started Jun 2018; status: completed.
02
Drugs
nivolumabgemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on KCT0003189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003189.